

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau




(43) International Publication Date
11 January 2001 (11.01.2001)

PCT

(10) International Publication Number
WO 01/02002 A1

- (51) International Patent Classification⁷: A61K 38/12, 47/26, 9/19
- (21) International Application Number: PCT/JP00/04381
- (22) International Filing Date: 29 June 2000 (29.06.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
11/187713 1 July 1999 (01.07.1999) JP
- (71) Applicant (for all designated States except US): FUJISAWA PHARMACEUTICAL CO., LTD. [JP/JP]; 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): SAWAI, Seiji [JP/JP]; 5-3-104, Yashiro-cho, Takarazuka-shi, Hyogo 665-0071 (JP). KASAI, Akihiro [JP/JP]; 5-1-2-606, Haginodai, Ikoma-shi, Nara 630-0224 (JP). OTOMO, Kazumi [JP/JP]; 11-3, Funaki-cho, Ibaraki-shi, Osaka 567-0828 (JP).
- (74) Agent: NOGAWA, Shintaro; Minamimorimachi Park Building, 1-3, Nishitenma 5-chome, Kita-ku, Osaka-shi, Osaka 530-0047 (JP).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— With international search report.
— Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: STABILIZED PHARMACEUTICAL COMPOSITION IN LYOPHILIZED FORM



(57) Abstract: A stabilized pharmaceutical composition in lyophilized form comprising: a cyclic polypeptide compound represented by general formula (I) wherein R¹ is a hydrogen atom or an acyl group and R² and R³ are, the same or different, a hydrogen atom or a hydroxyl group, or a salt thereof and one or more stabilizer(s) selected from the group consisting of a polysaccharide, a disaccharide and sodium chloride.

(1)

WO 01/02002 A1

DESCRIPTION

STABILIZED PHARMACEUTICAL COMPOSITION
IN LYOPHILIZED FORM

5


TECHNICAL FIELD

The present invention relates to a stabilized pharmaceutical composition in lyophilized form containing a cyclic polypeptide compound. More particularly, the present invention relates to a

10 stabilized pharmaceutical composition in lyophilized form containing a cyclic polypeptide compound or its pharmaceutically acceptable salt and a stabilizer.

The cyclic polypeptide compound of the present invention is represented by the general formula (I):

15



wherein R^1 is a hydrogen atom or an acyl group and R^2 and R^3 are, the same or different, a hydrogen atom or a hydroxyl group. The compound has an antimicrobial activity, particularly an antifungal activity and a β

20 -1,3-glucan synthase inhibiting action, and is useful for preventing and treating various kinds of infectious diseases including Pneumocystis

carinii infection, e.g., carinii pneumonia.

BACKGROUND ART

Among the cyclic polypeptide compounds represented by the
5 above formula (I), a compound wherein R^1 is a hydrogen atom and R^2 and
 R^3 are hydroxyl groups and a compound wherein R^1 , R^2 and R^3 are
hydrogen atoms are obtained by a fermentation process disclosed by
European Patent No. 0462531 and processes disclosed by WO97/32975
and by WO97/47738. A compound wherein R^1 is an acyl group and its
10 production process are disclosed by US Patent Nos. 5,376,634 and
5,569,646 and WO96/11210 and WO99/40108.

The cyclic polypeptide compounds (I) and their salts are generally
unstable to light, humidity, acids, heat and the like. Therefore, desired
is development of pharmaceutical preparations in which the cyclic
15 polypeptide compounds and their salts are stabilized.

DISCLOSURE OF INVENTION

The present invention provides a stabilized pharmaceutical
composition in lyophilized form containing a cyclic polypeptide
20 compound (I) or its pharmaceutically acceptable salt and a stabilizer.

The "acyl group" for R^1 in the formula (I) representing the cyclic
polypeptide compound of the present invention is now explained. In the
context of the present specification, "lower" means having one to six
carbon atoms unless otherwise indicated.

25 As examples of the acyl group, may be mentioned aliphatic acyl
groups, aromatic acyl groups, aromatic-aliphatic acyl groups and
heterocyclic acyl groups derived from aliphatic, aromatic, aromatic-
aliphatic and heterocyclic carboxylic acids.

Examples of the aliphatic acyl groups include lower or higher
30 alkanoyl groups such as formyl, acetyl, propanoyl, butanoyl, 2-
methylpropanoyl, pentanoyl, 2,2-dimethylpropanoyl, hexanoyl,
heptanoyl, octanoyl, nonanoyl, decanoyl, undecanoyl, dodecanoyl,
tridecanoyl, tetradecanoyl, pentadecanoyl, hexadecanoyl, heptadecanoyl,

octadecanoyl, nonadecanoyl, icosanoyl, etc.; cycloalkanoyl groups such as cyclopentanoyl and cyclohexanoyl; lower alkoxycarbonyl groups such as methoxycarbonyl, ethoxycarbonyl, t-butoxycarbonyl, t-pentyloxycarbonyl, heptyloxycarbonyl, etc.; lower alkanesulfonyl groups
5 such as methanesulfonyl, ethanesulfonyl, etc.; lower alkoxysulfonyl groups such as methoxysulfonyl, ethoxysulfonyl, etc.; and the like.

Examples of the aromatic acyl groups include aroyl groups such as benzoyl, toluoyl, naphthoyl and the like.

Examples of the aromatic-aliphatic acyl groups include
10 ar(lower)alkanoyl groups such as phenyl(C₁-C₆)alkanoyl (e.g., phenylacetyl, phenylpropanoyl, phenylbutanoyl, phenylisobutanoyl, phenylpentanoyl, phenylhexanoyl, etc.), naphthyl(C₁-C₆)alkanoyl (e.g., naphthylacetyl, naphthylpropanoyl, naphthylbutanoyl, etc.) and the like;
15 ar(lower)alkenoyl groups such as phenyl(C₃-C₆)alkenoyl (e.g., phenylpropenoyl, phenylbutenoyl, phenylmethacryloyl, phenylpentanoyl, phenylhexenoyl, etc.), naphthyl (C₃-C₆)alkenoyl (e.g., naphthylpropenoyl, naphthylbutenoyl, etc.) and the like;
ar(lower)alkoxycarbonyl groups such as phenyl(C₁-C₆)alkoxycarbonyl (e.g., benzyloxycarbonyl, etc.), fluorenyl (C₁-C₆) alkoxycarbonyl (e.g.,
20 fluorenylmethoxycarbonyl, etc.) and the like;
aryloxycarbonyl groups such as phenoxycarbonyl, naphthoxycarbonyl, etc.;
aryloxy(lower)alkanoyl groups such as phenoxyacetyl, phenoxypropionyl, etc.;
25 arylcarbamoyl groups such as phenylcarbamoyl, etc.;
arylthiocarbamoyl groups such as phenylthiocarbamoyl, etc.;
arylglyoxyloyl groups such as phenylglyoxyloyl, naphthylglyoxyloyl, etc.;
arylsulfonyl groups which may be optionally substituted by a lower alkyl group such as phenylsulfonyl, p-tolylsulfonyl, etc.; and the like.

30 Examples of the heterocyclic acyl groups include heterocyclic carbonyl groups such as thenoyl, furoyl, nicotinoyl, etc.;
heterocyclic(lower)alkanoyl groups such as heterocyclic acetyl, heterocyclic propanoyl, heterocyclic butanoyl, heterocyclic pentanoyl,

heterocyclic hexanoyl, etc.;
heterocyclic(lower)alkenoyl groups such as heterocyclic propenoyl,
heterocyclic butenoyl, heterocyclic pentenoyl, heterocyclic hexenoyl, etc.;
heterocyclic glyoxyloyl and the like.

- 5 The acyl group for R¹ may have one or more suitable
substituent(s). Among the above-mentioned examples for the acyl
groups, an aroyl group which may have one or more suitable
substituent(s) is particularly preferable.

- Examples of suitable substituents in the acyl group include a
10 heterocyclic group substituted by an aryl group having a lower alkoxy
group, a heterocyclic group substituted by an aryl group having a lower
alkoxy(lower)alkoxy group, a heterocyclic group substituted by an aryl
group having a lower alkoxy(higher)alkoxy group, a heterocyclic group
substituted by an aryl group having a cyclo(lower)alkyloxy group, a
15 heterocyclic group substituted by an aryl group having a heterocyclic
group, a heterocyclic group substituted by a cyclo(lower)alkyl group
having a cyclo(lower)alkyl group, a heterocyclic group substituted by an
aryl group having an aryl group substituted by a lower
alkoxy(lower)alkoxy and a heterocyclic group substituted by an aryl
20 group having a heterocyclic group substituted by a cyclo(lower)alkyl
group.

- Among these examples, preferred are an unsaturated 3- to 8-
membered heteromonocyclic group containing one to two oxygen atom(s)
and one to three nitrogen atom(s) and substituted by phenyl having (C₄-
25 C₆)alkoxy, an unsaturated condensed heterocyclic group containing one
to two sulfur atom(s) and one to three nitrogen atom(s) and substituted
by phenyl having (C₄-C₆)alkoxy, an unsaturated 3- to 8-membered
heteromonocyclic group containing one to two sulfur atom(s) and one to
three nitrogen atom(s) and substituted by phenyl having (C₁-
30 C₄)alkoxy(C₄-C₆)alkoxy, an unsaturated 3- to 8-membered
heteromonocyclic group containing one to two sulfur atom(s) and one to
three nitrogen atom(s) and substituted by phenyl having (C₁-
C₄)alkoxy(C₇-C₁₄)alkoxy, a saturated 3- to 8-membered heteromonocyclic






group containing one to four nitrogen atom(s) and substituted by phenyl having (C₁-C₄)alkoxy(C₇-C₁₄)alkoxy, an unsaturated condensed heteromonocyclic group containing one to two sulfur atom(s) and one to three nitrogen atom(s) and substituted by phenyl having cyclo(C₄-C₆)alkyloxy, an unsaturated condensed heterocyclic group containing one to two sulfur atom(s) and one to three nitrogen atom(s) and substituted by phenyl, a saturated 3- to 8-membered heteromonocyclic group containing one to two oxygen atom(s) and one to three nitrogen atom(s), a saturated 3- to 8-membered heteromonocyclic group having one to four nitrogen atom(s) and substituted by cyclo(C₄-C₆)alkyl having cyclo(C₄-C₆)alkyl, an unsaturated 3- to 8-membered heteromonocyclic group having one to two sulfur atom(s) and one to three nitrogen atom(s) and substituted by phenyl having phenyl substituted by (C₁-C₄)alkoxy(C₁-C₄)alkoxy, an unsaturated 3- to 8-membered heteromonocyclic group containing one to two sulfur atom(s) and one to three nitrogen atom(s) and substituted by phenyl having a saturated 3- to 8-membered heteromonocyclic group which contains one to four nitrogen atom(s) and is substituted by cyclo(C₄-C₆)alkyl, and an unsaturated condensed heterocyclic group containing one to two sulfur atom(s) and one to three nitrogen atom(s) and substituted by phenyl having a saturated 3- to 8-membered heteromonocyclic group which contains one to four nitrogen atom(s) and has cyclo(C₄-C₆)alkyl.

Among these, particularly preferred are an isoxazolyl group substituted by phenyl having pentyloxy, an imidazothiadiazolyl group substituted by phenyl having pentyloxy, a thiadiazolyl group substituted by phenyl having methoxyhexyloxy, a thiadiazolyl group substituted by phenyl having methoxyoctyloxy, a thiadiazolyl group substituted by phenyl having methoxyheptyloxy, an imidazothiadiazolyl group substituted by phenyl having cyclohexyloxy, an imidazothiadiazolyl group substituted by phenyl having dimethylmorpholino, a piperazinyl group substituted by phenyl having methoxyheptyloxy, a piperazinyl group substituted by phenyl having methoxyoctyloxy, a piperazinyl group substituted by cyclohexyl having cyclohexyl, a thiadiazolyl group

substituted by phenyl having phenyl substituted by methoxyethoxy, a
thiadiazolyl group substituted by phenyl having phenyl substituted by
methoxybutoxy, a thiadiazolyl group substituted by phenyl having
phenyl substituted by ethoxypropoxy, an imidazothiadiazolyl group
5 substituted by phenyl having piperazinyl substituted by cyclohexyl, an
imidazothiadiazolyl group substituted by phenyl having piperazinyl
substituted by cyclohexyl, and the like.

Accordingly, particularly suitable examples of the acyl group of
R¹ may be a benzoyl group having isoxazolyl substituted by phenyl
10 having pentyloxy, a benzoyl group having imidazothiadiazolyl
substituted by phenyl having pentyloxy, a benzoyl group having
thiadiazolyl substituted by phenyl having methoxyhexyloxy, a benzoyl
group having thiadiazolyl substituted by phenyl having methoxyoctyloxy,
a benzoyl group having thiadiazolyl substituted by phenyl having
15 methoxyheptyloxy, a benzoyl group having imidazothiadiazolyl
substituted by phenyl having cyclohexyloxy, a benzoyl group having
imidazothiadiazolyl substituted by phenyl having dimethylmorpholino, a
benzoyl group having piperazinyl substituted by phenyl having
methoxyheptyloxy, a benzoyl group having piperazinyl substituted by
20 phenyl having methoxyoctyloxy, a benzoyl group having piperazinyl
substituted by cyclohexyl having cyclohexyl, a benzoyl group having
thiadiazolyl substituted by phenyl having phenyl substituted by
methoxyethoxy, a benzoyl group having thiadiazolyl substituted by
phenyl having phenyl substituted by methoxybutoxy, a benzoyl group
25 having thiadiazolyl substituted by phenyl having phenyl substituted by
ethoxypropoxy, a benzoyl group having imidazothiadiazolyl substituted
by phenyl having piperazinyl substituted by cyclohexyl, a benzoyl group
having imidazothiadiazolyl substituted by phenyl having piperazinyl
substituted by cyclohexyl, and the like.

30 Particularly preferable examples of the acyl groups of R¹ are
represented by the formulas:



The cyclic polypeptide compounds (I) having the above-mentioned acyl groups may be prepared from a compound having a hydrogen atom as R¹ and hydroxyl groups as R² and R³ or a compound
 5 having hydrogen atoms as R¹, R² and R³ according to the US Patent Nos. 5,376,634 and 5,569, 646 and WO96/11210 and WO99/40108.

Suitable salts of the cyclic polypeptide compounds (I) are soluble in water and pharmaceutically acceptable salts including salts with bases and acid addition salts. Such a salt may be prepared by treating
 10 the cyclic polypeptide compound (I) with an appropriate base or acid according to the conventional method.

As salts with bases, may be mentioned salts with inorganic bases such as alkali metal salts (e.g., sodium salts, potassium salts, etc.), alkaline earth metal salts (e.g., calcium salts, magnesium salts, etc.),




ammonium salts and the like; salts with organic bases such as organic amine salts (e.g., triethylamine salts, diisopropylethylamine salts, pyridine salts, picoline salts, ethanolamine salts, triethanolamine salts, dicyclohexylamine salts, N,N'-dibenzylethylenediamine salts, etc.); and
5 the like.



As acid addition salts, may be mentioned inorganic acid addition salts (e.g., hydrochlorides, hydrobromides, sulfates, phosphates, etc.); and organic carboxylic or sulfonic acid addition salts (e.g., formates, acetates, trifluoroacetates, maleates, tartrates, fumarates,
10 methnesulfonates, benzenesulfonates, toluenesulfonates, etc.). Further, may also be mentioned salts with basic or acidic amino acids (e.g., salts with arginine, aspartic acid, glutamic acid, etc.).

The cyclic polypeptide compounds (I) of the present invention also include possible conformers and a pair or more of stereoisomers
15 such as geometric isomers and optical isomers which may exist due to asymmetric carbon atoms.

The preferable ones of the cyclic polypeptide compounds (I) are represented by the following formulas (II) to (VI):
(to be continued on the next page)

20





The most preferable one is represented by the formula (II).

The amount of the cyclic polypeptide compound (I) or its
 5 pharmaceutically acceptable salt contained in the composition for a
 single unit dosage of the present invention is 0.1 to 400 mg, more
 preferably 1 to 200 mg, still more preferably 10 to 100 mg, specifically 10,
 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 70, 75, 80, 85, 90, 95 and 100 mg.

As the stabilizer, may be mentioned polysaccharides,
 10 disaccharides, sodium chloride and a combination thereof.

Examples of the polysaccharide are dextran, starch, cellulose

and hyaluronic acid; and examples of the disaccharide are lactose, maltose and sucrose. The polysaccharide or disaccharide contained in the pharmaceutical composition of the present invention may be α -monohydrate, α -anhydride, β -anhydride or a combination thereof.

5 The amount of the stabilizer used in the pharmaceutical composition of the present invention should be at least sufficient for stabilizing the cyclic polypeptide compound (I) or its pharmaceutically acceptable salt in the composition. In order to stabilize the cyclic polypeptide compound (I), one part by weight of the stabilizer with
10 respect to one part by weight of the cyclic polypeptide compound (I) or its pharmaceutically acceptable salt in the present composition is sufficient at least. The stabilizer may also serve as a carrier or an excipient. Thus the use amount of stabilizer does not have a particular upper limit and may be determined in consideration of the weight or volume of the
15 composition with respect to a unit dose of the compound and the like. However, such amount is preferably 0.4 to 50 parts by weight, more preferably 0.6 to 20 parts by weight, still more preferably 0.8 to 10 parts by weight with respect to one part by weight of the cyclic polypeptide compound (I) or its pharmaceutically acceptable salt, though it varies
20 depending upon the kind and the used amount of the cyclic polypeptide compound (I) or its pharmaceutically acceptable salt, its preparation form and/or the like. Specifically, it is more preferable that 1 to 20 parts, still more preferably 2 to 10 parts by weight of the disaccharide are used with respect to one part by weight of the cyclic polypeptide
25 compound (I) or its pharmaceutically acceptable salt. Specifically, it is more preferable that 0.6 to 20 parts, still more preferably 0.8 to 10 parts by weight of sodium chloride are used with respect to one part by weight of the cyclic polypeptide compound (I) or its pharmaceutically acceptable salt.

30 The pharmaceutical composition of the present invention may be produced according to methods known in the art with using additives if necessary. Here, *Basic Lecture on Development of Pharmaceuticals XI 20 Production of Pharmaceuticals (the second volume) (edited by Kyobunn*

Tsuda and Hisashi Nogami and published by Chizyo Shoten) is mentioned for reference. The lyophilized composition may be obtained by preparing an aqueous solution of the cyclic polypeptide compound (I) or its pharmaceutically acceptable salt and the stabilizer, optionally adding a pH adjustor (citric acid anhydrous, sodium hydroxide, etc.) as required to attain pH 4.0 - 7.5, preferably pH 4.5 - 7.0, and then lyophilizing the resulting solution in vial according to a conventional method. Thus, the stabilized pharmaceutical composition in lyophilized form, when dissolved in purified water, preferably gives a solution of pH 4.0 to 7.5, more preferably pH 4.5 to 7.0. It is preferable that the thus prepared composition in lyophilized form is sealed and stored with shading. The lyophilized composition can be loaded in each vial in the solution form before lyophilizing or in lyophilized powder form after lyophilizing.

Since the cyclic polypeptide compound is not satisfactorily stable to humidity, it is necessary that the lyophilized composition of the present invention contains 3.4 % by weight or less of water, preferably 3.0 %, more preferably 2.0 %.

Usually the stabilized pharmaceutical composition in lyophilized form is dissolved in isotonic sodium chloride solution as required and used as an injection solution. The pharmaceutical composition of the present invention may be used as an injection preparation which requires some compounding before use.

BEST MODE FOR CARRYING OUT THE INVENTION

The present invention is now described in further detail by way of examples and test examples, which should not be construed to limit the scope of the invention. In the examples, the compounds of formula (II) to (VI) are referred to as Compounds (II) to (VI), respectively.

Example 1

Compound (II) 25 g

Lactose 200 g

anhydrous Citric acid in a suitable amount

Sodium hydroxide in a suitable amount

Lactose was dissolved in purified water (2000 ml) under heating below 50°C. After cooling below 20°C, the lactose solution was added
5 with Compound (II) avoiding bubbling under gently stirring. After adding 2 % aqueous citric acid solution (9.5 ml), the solution was added with 0.4 % aqueous sodium hydroxide solution (about 24 ml) to adjust pH 5.5 followed by diluting with purified water to make a given volume (2500 ml). The resulting solution was dispensed into 1,000 vials of 10
10 mL volume, 2.5 ml per vial. The solution in the respective vials was lyophilized by using the lyophilizer (RL-603BS manufactured by Kyowa Shinku Co., Ltd) by the conventional method to obtain lyophilized compositions each containing 25 mg of Compound (II).

15 Example 2

Lyophilized compositions each containing 50 mg of Compound (II) were obtained in the same manner as in Example 1 except that the amount of Compound (II) used was 50 g.

20 Example 3

Lyophilized compositions each containing 25 mg of Compound (II) are obtained in the same manner as in Example 1 except that 150 g of maltose is used instead of lactose.

25 Example 4

Lyophilized compositions each containing 50 mg of Compound (II) are obtained in the same manner as in Example 1 except that the amount of Compound (II) used is 50 g instead of 25 g and 250 g of sucrose is used instead of lactose.

30

Example 5

Lyophilized compositions each containing 25 mg of Compound (II) are obtained in the same manner as in Example 1 except that 25 g of

sodium chloride is used instead of lactose.

Example 6

5 Lyophilized compositions each containing 10 mg of Compound (II) are obtained in the same manner as in Example 1 except that the amount of Compound (II) used is 10 g instead of 25 g and 100 g of dextran is used instead of lactose.

Example 7

10 Lyophilized compositions each containing 25 mg of Compound (III) are obtained in the same manner as in Example 1 except that 25 g of Compound (III) is used instead of Compound (II) and 200 g of maltose is used instead of lactose.

15 Example 8

Lyophilized compositions each containing 10 mg of Compound (IV) are obtained in the same manner as in Example 1 except that 10 g of Compound (IV) is used instead of Compound (II) and the amount of lactose used is 100 g instead of 200 g.

20

Example 9

Lyophilized compositions each containing 50 mg of Compound (V) are obtained in the same manner as in Example 1 except that 50 g of Compound (V) is used instead of Compound (II) and 50 g of sodium
25 chloride is used instead of lactose.

Example 10

Lyophilized compositions each containing 10 mg of Compound (VI) are obtained in the same manner as in Example 1 except that 10 g of
30 Compound (VI) is used instead of Compound (II) and 100 g of dextran is used instead of lactose.

Test Example 1

Effect of stabilizer in stabilizing lyophilized compositions of Compound (II)

10 mg of Compound (II) and, as a stabilizer, 100 mg of lactose or 9 mg of sodium chloride were dissolved completely in 1 ml of water. The resulting solutions were lyophilized and maintained at 70°C in glass vials. Nine days after, the resulting compositions were tested on their appearance, the residual amount of Compound (II), and others. As a control, used was a solution of Compound (II) without any stabilizers. The results are shown in Table 1.

10

Table 1

Stabilizers	Test Items	0 hours	After 9 days
Control : nil	Appearance	White mass	Slightly yellow mass
	pH *	7.1	2.7
	Residual amount (%)	100.0	8.0
	Water content (%)	1.3	-
Lactose (100 mg)	Appearance	White mass	White mass
	pH *	6.4	6.1
	Residual amount (%)	100.0	99.5
	Water content (%)	1.0	-
Sodium chloride (9 mg)	Appearance	White mass	White mass
	pH *	6.7	6.3
	Residual amount (%)	100.0	75.9
	Water content (%)	0.7	-

* pH of reconstituted solutions of compositions in 1 ml of water

Test Example 2

15 The similar tests were conducted in the same manner as in Test Example 1 except that 100 mg of maltose, 50 mg of sucrose or 50 mg of glucose was used as a stabilizer. The results are shown in Table 2.
(to be continued on the next page)

Table 2

Stabilizers	Test Items	0 hours	After 9 days
Control : nil	Appearance	White mass	White mass
	pH *	6.8	5.4
	Residual amount (%)	100.0	<75.0
	Water content (%)	3.3	-
Maltose (100 mg)	Appearance	White mass	White mass
	pH *	7.3	6.7
	Residual amount (%)	100.0	98.6
	Water content (%)	0.9	-
Sucrose (50 mg)	Appearance	White mass	White melt
	pH *	6.9	7.0
	Residual amount (%)	100.0	82.4
	Water content (%)	1.1	-
Glucose (50 mg)	Appearance	White melt	Brown melt
	pH *	6.9	3.6
	Residual amount (%)	100	1.1
	Water content (%)	4.3	-

* pH of reconstituted solutions of compositions in 1 ml of water

- As is obvious from Tables 1 and 2, the lyophilized composition of
- 5 Compound (II) and lactose, sodium chloride, maltose or sucrose was significantly stable as compared with the one not containing any stabilizers or containing other stabilizers.

Test Example 3

- 10 Dependence of the stability of lyophilized compositions of Compound (II) upon the amount of lactose added

Tests were carried out in the same manner as in Test example 1 except that 20 mg, 50 mg, 100 mg or 200 mg of lactose were added as a stabilizer. Table 3 shows the results of tests by observation of the

15 appearance of compositions, the residual amount of Compound (II), the appearance of reconstituted solutions of compositions in 1 ml of water, and the like. Incidentally, it took 15 seconds to reconstitute the compositions in 1 ml of water.

Table 3

Amount of lactose added (mg)	Test Items	0 hours	After 9 days at 70°C	After 3 months at 40°C and a 75% humidity
20	Appearance	White mass	Slightly yellow mass	White mass
	Color *	Colorless	White	Colorless
	Clarity *	Clear	Not clear	Clear
	pH *	6.09	3.03	6.57
	Residual amount (%)	100.0	88.09	100.0
	Total impurities (%)	3.44	12.3	3.99
	Water content (%)	1.2	-	-
50	Appearance	White mass	White mass	White mass
	Color *	Colorless	Colorless	Colorless
	Clarity *	Clear	Clear	Clear
	pH *	6.57	5.56	6.26
	Residual amount (%)	100.0	96.7	99.8
	Total impurities (%)	3.32	7.37	4.21
	Water content (%)	0.5	-	-
100	Appearance	White mass	White mass	White mass
	Color *	Colorless	Colorless	Colorless
	Clarity *	Clear	Clear	Clear
	pH *	6.58	6.08	5.80
	Residual amount (%)	100.0	96.7	99.6
	Total impurities (%)	3.43	7.08	3.96
	Water content (%)	0.3	-	-
200	Appearance	White mass	White mass	White mass
	Color *	Colorless	Colorless	Colorless
	Clarity *	Clear	Clear	Clear
	pH *	6.78	5.70	5.36
	Residual amount (%)	100.0	96.1	99.6
	Total impurities (%)	3.40	7.30	4.35
	Water content (%)	0.3	-	-

* Color, clarity and pH of reconstituted solutions of compositions in 1 ml of water

5 As is obvious from Table 3, the lyophilized compositions of 10 mg of Compound (II) and various amount of lactose had no problem in their stability.

Test Example 4

Stability of lyophilized compositions of 200 mg of lactose and Compound (II) in vial

- 5 Tests were carried out in the same manner as in Test Example 1 except that 12.5 mg, 25 mg, 50 mg, 75 mg or 100 mg of Compound (II) were used with 200 mg of lactose. Table 4 shows the results of the tests on the residual amount of Compound (II) in the resulting compositions and the like. Regarding all the compositions, their appearance is a
- 10 white mass, the time for reconstitutorial dissolution was 15 seconds, and the color and the clarity of reconstituted solutions of the compositions were colorless and transparent.

Table 4

Amount of Compound (II) added (mg)	Test Items	0 hours	After 9 days at 70°C	After 21 days at 60°C	After 3 months at 40°C and a 75% humidity
12.5	pH *	6.63	6.15	6.31	6.08
	Residual amount (%)	100.0	98.1	97.5	99.6
	Total impurities (%)	2.24	3.95	3.75	2.71
	Water content (%)	1.3	-	-	-
25	pH *	6.37	6.07	6.11	6.14
	Residual amount (%)	100.0	99.3	98.2	101.2
	Total impurities (%)	2.25	4.03	3.49	2.68
	Water content (%)	1.1	-	-	-
50	pH *	6.26	5.99	6.00	6.00
	Residual amount (%)	100.0	97.9	97.3	100.5
	Total impurities (%)	2.25	3.95	3.68	2.74
	Water content (%)	1.2	-	-	-
75	pH *	6.13	5.95	5.96	6.04
	Residual amount (%)	100.0	98.1	97.7	99.0
	Total impurities (%)	2.28	4.14	3.83	2.76
	Water content (%)	0.9	-	-	-
100	pH *	6.03	5.92	5.88	5.85
	Residual amount (%)	100.0	97.8	96.7	99.5
	Total impurities (%)	2.46	4.15	3.92	2.79
	Water content (%)	1.3	-	-	-

* pH of reconstituted solutions of compositions in 5 ml of purified water

As is obvious from Table 4, all the lyophilized compositions were stable.

5

Test Example 5

Stability test

The pharmaceutical compositions obtained in Examples 1 and 2 were stored at room temperature. After 18 months, the residual ratio of
10 Compound (II) was 98 % in all the compositions.

Test Example 6

Dependence of the stability of lyophilized compositions of Compound (II) upon the pH value of the solution of the composition before lyophilizing
15 10 mg of Compound (II) and, as a stabilizer, 100mg of lactose were dissolved completely in 1 ml of citrate-NaOH buffer having different pH value between pH 4.0 to 7.0. The resulting solutions having different pH values were lyophilized and maintained at 70°C in glass vials. Nine days after, the resulting compositions were tested on their pH and the
20 residual amount of Compound (II). The results are shown in Table 5.

Table 5

	pH of the solution of the composition before lyophilizing	4.0	4.5	5.0	5.5	6.0	6.5	7.0
0 hours	pH*	3.9	4.4	4.8	5.4	5.8	6.4	6.8
	Water content (%)	0.2	0.2	0.3	0.3	0.3	0.4	0.3
	Residual amount (%)	100						
9 days	pH*	4.0	4.5	4.9	5.4	5.8	6.4	6.8
	Residual amount (%)	94.4	95.9	97.4	98.5	97.7	96.9	95.8

* pH of reconstituted solutions of compositions in 5 ml of purified water

As is obvious from the table 5, the pharmaceutical composition of the present invention is stable after lyophilizing the solution containing Compound (II) at pH 4.0 to 7.0 at least, preferably at pH 4.5 to 7.0.

5

Test Example 7

Dependence of the stability of lyophilized compositions of Compound (II) upon the water content of the composition

10 10 mg of Compound (II) and, as a stabilizer, 50mg of lactose were dissolved completely in 1 ml of water. The resulting solutions were lyophilized and maintained at 70°C in glass vials. Nine days after, the resulting compositions were tested on their pH, their water content and the residual amount of Compound (II). The results are shown in Table 6.

15

Table 6

Water content at 0 hours (%)		0.9	1.4	2.6	3.4	5.1
0 hours	pH*	7.1				
After 9 days	pH*	7.5	7.1	6.8	6.8	3.5
	Water content (%)	2.5	2.9	3.6	4.3	5.4
	Residual amount (%)	97.6	98.1	97.1	92.7	18.3

* pH of reconstituted solutions of compositions in 1 ml of water

20 As is obvious from Table 6, the pharmaceutical composition of the present invention is stable containing about 3.5 %, more particularly 3.4 % by weight or less of water.

25 According to the present invention, provided is a composition in lyophilized form in which the cyclic polypeptide compound (I) or its pharmaceutically acceptable salt are stabilized by a stabilizer such as polysaccharide, disaccharide and sodium chloride.

The mechanism of the stabilization of the cyclic polypeptide compound (I) or its pharmaceutically acceptable salt by the stabilizer such as polysaccharide, disaccharide and sodium chloride is still to be unknown, but it may be that the stabilizer adsorbs water in lyophilized cakes and that the stabilizer serves to disperse the compound or its pharmaceutically acceptable salt uniformly in the composition.

The cyclic polypeptide compound (I) has an antifungal activity, particularly against the following fungi.

- 10 *Acremonium*;
 Absidia (e.g., *Absidia corymbifera*, etc);
 Aspergillus (e.g., *Aspergillus clavatus*, *Aspergillus flavus*, *Aspergillus fumigatus*, *Aspergillus nidulans*, *Aspergillus niger*, *Aspergillus terreus*, *Aspergillus versicolor*, etc);
- 15 *Blastomyces* (e.g., *Blastomyces dermatitidis*, etc);
 Candida (e.g., *Candida albicans*, *Candida glabrata*, *Candida guilliermondii*, *Candida kefyr*, *Candida krusei*, *Candida parapsilosis*, *Candida stellatoidea*, *Candida tropicalis*, *Candida utilis*, etc);
 Cladosporium (e.g., *Cladosporium trichoides*, etc);
- 20 *Coccidioides* (e.g., *Coccidioides immitis*, etc);
 Cryptococcus (e.g., *Cryptococcus neoformans*, etc);
 Cunninghamella (e.g., *Cunninghamella elegans*, etc);
 Dermatophyte;
 Exophiala (e.g., *Exophiala dermatitidis*, *Exophiala spinifera*, etc);
- 25 *Epidermophyton* (e.g., *Epidermophyton floccosum*, etc);
 Fonsecaea (e.g., *Fonsecaea pedrosoi*, etc);
 Fusarium (e.g., *Fusarium solani*, etc);
 Geotrichum (e.g., *Geotrichum candidum*, etc);
 Histoplasma (e.g., *Histoplasma capsulatum* var. *capsulatum*, etc);
- 30 *Malassezia* (e.g., *Malassezia furfur*, etc);
 Microsporum (e.g., *Microsporum canis*, *Microsporum gypseum*, etc);
 Mucor;
 Paracoccidioides (e.g., *Paracoccidioides brasiliensis*, etc);

- Penicillium* (e.g., *Penicillium marneffei*, etc);
Phialophora;
Pneumocystis (e.g., *Pneumocystis carinii*, etc);
Pseudallescheria (e.g., *Pseudallescheria boydii*, etc);
5 *Rhizopus* (e.g., *Rhizopus microsporus* var. *rhizopodiformis*, *Rhizopus*
oryzae, etc);
Saccharomyces (e.g., *Saccharomyces cerevisiae*, etc);
Scopulariopsis;
Sporothrix (e.g., *Sporothrix schenckii*, etc);
10 *Trichophyton* (e.g., *Trichophyton mentagrophytes*, *Trichophyton*
rubrum, etc);
Trichosporon (e.g., *Trichosporon asahii*, *Trichosporon cutaneum*, etc).


The above fungi are well known to cause various infection diseases in skin, hair, nail, oral mucosa, gastrointestinal tract, bronchus,
15 lung, endocardium, brain, meninges, urinary organ, vaginal protion, oral cavity, ophthalmus, systemic, kidney, bronchus, heart, external auditory canal, bone, nasal cavity, paranasal cavity, spleen, liver, hypodermal tissue, lymph duct, gastrointestinal, articulation, muscle, tendon, interstitial plasma cell in lung, and so on.

20 Therefore, the cyclic polypeptide compound (I) of the present composition is useful for preventing and treating various infectious diseases, such as dermatophytosis (e.g., trichophytosis, etc), pityriasis versicolor, candidiasis, cryptococcosis, geotrichosis, trichosporosis, aspergillosis, penicilliosis, fusariosis, zygomycosis, sporotrichosis,
25 chromomycosis, coccidioidomycosis, histoplasmosis, blastomycosis, paracoccidioidomycosis, pseudallescheriosis, mycetoma, mycotic keratitis, otomycosis, pneumocystosis, and so on.

A commercial package comprising the cyclic polypeptide compound (I) of the present composition and a written matter associated
30 therewith, wherein the written matter states that the pharmaceutical composition can or should be used for preventing or treating infections disease.


CLAIMS

1. A stabilized pharmaceutical composition in lyophilized form which comprises:
- 5 a cyclic polypeptide compound of the general formula (I) :



- wherein R^1 is a hydrogen atom or an acyl group and R^2 and R^3 are, the same or different, a hydrogen atom or a hydroxyl group,
- 10 or its pharmaceutically acceptable salt as an active ingredient, and one or more suitable stabilizer(s) selected from the group consisting of a polysaccharide, a disaccharide and sodium chloride.

2. A composition according to claim 1 in which R^1 is represented by
- 15 the formula:



and R^2 and R^3 are hydroxy groups.

3. A composition according to claim 1 in which the stabilizer is a disaccharide.
4. A composition according to claim 3 in which the disaccharide is
5 lactose, maltose or sucrose.
5. A composition according to claim 4 in which the disaccharide is lactose.
- 10 6. A composition according to claim 1 which contains 0.4 to 50 parts by weight of the stabilizer with respect to one part by weight of the cyclic polypeptide compound or its pharmaceutically acceptable salt.
7. A composition according to claim 1 which contains 0.1 to 400 mg
15 of the cyclic polypeptide compound or its pharmaceutically acceptable salt in a single unit dose.
8. A composition according to claim 1 prepared by the steps of:
dissolving the cyclic polypeptide compound (I) or its pharmaceutically
20 acceptable salt, the stabilizer and optionally a pH adjustor in a purified water and
lyophilizing the solution.
9. A composition of claim 1 which, when dissolved in purified water,
25 gives a solution of pH 4.0 to 7.5.
10. A composition of claim 1 containing 3.4 % by weight or less of water.
- 30 11. A use of the cyclic polypeptide compound (I) or its pharmaceutically acceptable salt for preparing the stabilized pharmaceutical composition in lyophilized form containing the stabilizer.

12. An injection preparation prepared by dissolving the composition of claim 1 in isotonic sodium chloride solution.
13. A use of a polysaccharide, a disaccharide and sodium chloride as
5 a stabilizer for a stabilized pharmaceutical composition in lyophilized form.
14. A use according to claim 13, wherein the stabilized
pharmaceutical composition in lyophilized form is a composition as set
10 forth in claim 1.
15. A commercial package comprising the pharmaceutical
composition of any one of claim 1 to claim 10 and a written matter
associated therewith, wherein the written matter states that the
15 pharmaceutical composition can or should be used for preventing or
treating infections disease.

INTERNATIONAL SEARCH REPORT

Intern Application No
PCT/JP 00/04381

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K38/12 A61K47/26 A61K9/19

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 39763 A (MERCK & CO INC ;NERURKAR MANEESH J (US); HUNKE WILLIAM A (US); KAU) 30 October 1997 (1997-10-30) page 2, line 1 -page 3, line 9 page 13; example 1 ----	1-15
A	TOYO JOZO KK: "New cyclo:polypeptide antibiotic- for treatment of pneumonia caused by Pneumocystis carinii" , WPI WORLD PATENT INFORMATION DERWENT,GB,DERWENT, VOL. 91, NR. 30 XP002144088 abstract ----	1-15
T	WO 00 51567 A (LILLY CO ELI ;TAYLOR JERRY (US); SCHWIER JOHN RICHARD (US)) 8 September 2000 (2000-09-08) page 5, line 19 -page 6, line 21 ----- -/-	1-15

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"S" document member of the same patent family

Date of the actual completion of the international search

27 October 2000

Date of mailing of the international search report

06/11/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Muller, S

INTERNATIONAL SEARCH REPORT

Internat'l Application No
PCT/JP 00/04381

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	<p>WO 00 51564 A (SABATOWSKI JAMES LAWRENCE ; LILLY CO ELI (US); MILTON NATHANIEL (US) 8 September 2000 (2000-09-08) page 26, line 16 -page 28, line 1 claims 1,2,12,15 -----</p>	1-15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP 00/04381

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9739763 A	30-10-1997	AU 706250 B	10-06-1999
		AU 2731197 A	12-11-1997
		BG 102857 A	30-09-1999
		BR 9708706 A	03-08-1999
		CA 2251928 A	30-10-1997
		CZ 9803347 A	16-06-1999
		EP 0904098 A	31-03-1999
		HR 970201 A	31-08-1998
		HU 9901586 A	30-08-1999
		JP 11509555 T	24-08-1999
		NO 984860 A	18-12-1998
		PL 329442 A	29-03-1999
		SK 144898 A	07-05-1999
		US 5952300 A	14-09-1999
WO 0051567 A	08-09-2000	NONE	
WO 0051564 A	08-09-2000	NONE	